| Study |
Reference |
|
Choi a, 2023
|
Choi Association Between Proton Pump Inhibitor Use During Early Pregnancy and Risk of Congenital Malformations. JAMA Netw Open 2023; 6:e2250366
|
|
Choi b, 2023
|
Choi Maternal Proton Pump Inhibitor Use During Pregnancy and Risk of Low Birth Weight in Offspring in Korea, 2008-2019. JAMA Netw Open 2023; 6:e237962
|
|
Diav-Citrin, 2005
|
Diav-Citrin The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Aliment Pharmacol Ther 2005; 21:269-75
|
|
Fejzo, 2015
|
Fejzo MS Neurodevelopmental delay in children exposed in utero to hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol 2015;189:79-84
|
|
Fejzo, 2013
|
Fejzo Antihistamines and other prognostic factors for adverse outcome in hyperemesis gravidarum. Eur. J. Obstet. Gynecol. Reprod. Biol. 2013; 170:71-6
|
|
Källèn, 1998
|
Källén Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Br J Obstet Gynaecol 1998; 105:877-81
|
|
Lind, 2013
|
Lind Maternal medication and herbal use and risk for hypospadias: data from the National Birth Defects Prevention Study, 1997-2007. Pharmacoepidemiol Drug Saf 2013; 22:783-93
|
|
Matok, 2012
|
Matok The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig. Dis. Sci. 2012; 57:699-705
|
|
Pasternak, 2010
|
Pasternak Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N. Engl. J. Med. 2010; 363:2114-23
|
|
Yitshak-Sade, 2016
|
Yitshak-Sade Prenatal exposure to H2 blockers and to proton pump inhibitors and asthma development in offspring. J Clin Pharmacol 2016; 56:116-23
|
